RxDoctor Payments Data

Ronald Hart, MD

Family Medicine · Yuba City, CANPI 1356442032

Payments from drug & device makers

$60,169in general payments, 2019–2025

Across 1,740 payments — averaging $34.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$19K
  • Esperion Therapeutics, Inc.$7K
  • Novartis$6K
  • AbbVie$5K
  • AstraZeneca$3K
  • Amgen$3K
  • plus $17K from 54 others

What the payments were for

  • Consulting fees$18,25830%
  • Speaking & faculty fees$4,0007%
  • Travel & lodging$6,22010%
  • Food & beverage$31,36552%
  • Education$3251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer77$19,221
Esperion Therapeutics, Inc.77$6,824
Novartis61$6,299
AbbVie(2 entities)277$4,934
AstraZeneca127$3,149
Amgen172$2,806
Boehringer Ingelheim82$1,781
Lilly USA, LLC70$1,725
Amarin Pharma, Inc.98$1,386
Johnson & Johnson112$1,371
Merck58$1,224
Novo Nordisk63$1,129
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC69$1,117
Takeda Pharmaceuticals U.S.A., Inc.62$1,061
GSK54$1,030
Kowa Pharmaceuticals America, Inc.36$464
Pfizer29$424
Radius Health, Inc.9$247
Abbott12$245
Sanofi-aventis U.S. LLC11$207
Otsuka America Pharmaceutical, Inc.11$201
Astellas Pharma US Inc11$198
Phathom Pharmaceuticals, Inc.14$196
Paratek Pharmaceuticals, Inc.14$195
Medtronic(2 entities)3$168
Eisai Inc.9$163
Regeneron Healthcare Solutions, Inc.12$162
Corcept Therapeutics9$157
Tandem Diabetes Care, Inc.5$145
Alk-abello, Inc6$143
Daiichi Sankyo Inc.8$142
ANI Pharmaceuticals, Inc.6$135
Verity Pharmaceuticals Inc.6$124
Ironwood Pharmaceuticals, Inc6$100
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$93
Sanofi Pasteur Inc.5$91
Exact Sciences4$84
Heartflow, Inc.2$82
Dexcom, Inc.3$81
Axsome Therapeutics, Inc.2$75
Redhill Biopharma Inc.3$59
Biohaven Pharmaceutical Holding Company Ltd.3$58
IBSA Pharma Inc.3$58
E.r. Squibb & Sons, L.L.C.3$46
Scilex Pharmaceuticals Inc.2$42
Upsher-smith Laboratories LLC1$41
Lundbeck LLC2$40
Alfasigma USA, Inc.2$35
Biohaven Pharmaceuticals, Inc.2$34
Almatica Pharma LLC1$33
Idorsia Pharmaceuticals US Inc2$30
Mylan Specialty L.p.2$29
Mallinckrodt Hospital Products Inc.1$25
Fisher & Paykel Healthcare Inc1$25
Grifols USA, LLC1$21
Boston Scientific1$21
Corium, LLC1$20
Hologic Sales And Service, LLC1$19
Genentech USA, Inc.1$17
Acella Pharmaceuticals, LLC1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,169 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$779,401
Medicare patients
702
Services billed
11,112

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol471$502,197
OzempicSemaglutide394$417,599
Repatha SureclickEvolocumab228$225,696
KerendiaFinerenone194$215,577
EliquisApixaban153$197,928
MounjaroTirzepatide148$156,064
EntrestoSacubitril/Valsartan137$140,891
JardianceEmpagliflozin69$83,884
JanuviaSitagliptin Phosphate76$79,389
NexlizetBempedoic Acid/Ezetimibe95$55,344
XareltoRivaroxaban42$51,656
XifaxanRifaximin15$43,345
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog45$39,976
Ezetimibe1,100$36,715
Praluent PenAlirocumab35$32,817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$3,149$518,849496 claims
Novo NordiskOzempic$1,129$417,599394 claims
BayerKerendia$19,221$215,577194 claims
PfizerEliquis$424$197,928153 claims
Lilly USA, LLCMounjaro$1,725$156,064148 claims
NovartisEntresto$6,299$140,891137 claims
Boehringer IngelheimJardiance, Tradjenta$1,781$90,18981 claims
MerckJanuvia, Belsomra$1,224$84,65488 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$6,824$66,542118 claims
Johnson & JohnsonXarelto$1,371$51,65642 claims
AbbVieVraylar, Linzess, Synthroid$4,934$50,112160 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,117$43,34515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Yuba City

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →